Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.66 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30585954 | 0.98 | GRM5 (0.64) | GRM5SMYD3KMT2AKDM4EGAA | |
| Hydrochloric Acid SCHEMBL21640512 | 0.98 | GRM5 (0.64) | GRM5SMYD3KMT2AKDM4EGAA | |
| Acetic Acid SCHEMBL21641057 | 0.94 | GRM5 (0.59) | GRM5SMYD3KMT2AKDM4EGAA | |
| SCHEMBL14477846 | 0.88 | GRM5 (0.63) | GRM5SMYD3KMT2AKDM4EGAA | |
| SCHEMBL31654175 | 0.88 | GRM5 (0.63) | GRM5SMYD3KMT2AKDM4EGAA | |
| SCHEMBL31188521 | 0.88 | GRM5 (0.63) | GRM5SMYD3KMT2AKDM4EGAA | |
| SCHEMBL30385208 | 0.88 | GRM5 (0.63) | GRM5SMYD3KMT2AKDM4EGAA | |
| Hydrochloric Acid SCHEMBL28155964 | 0.87 | GRM5 (0.62) | GRM5SMYD3KMT2AKDM4EGAA | |
| Hydrochloric Acid SCHEMBL28156653 | 0.87 | GRM5 (0.62) | GRM5SMYD3KMT2AKDM4EGAA | |
| Hydrochloric Acid SCHEMBL28155966 | 0.87 | GRM5 (0.62) | GRM5SMYD3KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-9388164-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388164-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9221792-B2 | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators | AGIOS PHARMACEUTICALS, INC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221792-B2 | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators | AGIOS PHARMACEUTICALS, INC (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2651898-B1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL)PHENYL)-(HETERO-)ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2012151448-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012083246-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | PCK1, PDK3, PDK2 | GRM5 3687/4885SMYD3 3647/4885KMT2A 1518/4885 |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | PDK2, PDK3, PDK4 | GRM5 2619/4885SMYD3 2700/4885KMT2A 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.